impaired renal function. Our results indicate that a state ofnarcotic intoxication may exist in the absence of measurable amounts of morphine in the plasma. This may be explained by the persistence in the plasma of large quantities of the metabolite morphine-6-glucuronide, which is usually excreted renally.-Morphine-6-glucuronide (unlike morphine-3-glucuronide) is pharmacologically active in animals and, indeed, may be more potent than morphine itself.4 We believe that our findings are the first-recogised evidence of the pharmacological effect of morphine-6glucuronide in man.
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Previous studies ofpatients with renal failure seem to have shown abnormal elimination of morphine with reversion to normal when renal function returns after transplantation.' Extensive metabolism of morphine in the kidney has been suggested as a cause of this phenomenon. These findings, however, have been based on a radioimmunoassay for morphine which has been found to cross react extensively with morphine-6-glucuronide.5 Because more of this metabolite than morphine itself remains in the plasma after treatment with morphine, morphine concentrations measured with this radioimmunoassay in fact reflect the sum of morphine and morphine-6-glucuronide present, casting doubt on the results obtained with the assay.
The persistence of large amounts of morphine-6-glucuronide in the plasma, as described, is important for several reasons. Firstly, prolonged narcosis, long after the last dose of morphine is given, may result in incorrect diagnosis ofcerebral damage in the obtunded patient. Secondly, respiratory depression lasting for many days exposes the patient to the complications ofintubation and mechanical ventilation.
Finally, the fact that morphine-6-glucuronide may have been a confounding factor in many previous studies of morphine pharmacokinetics that used radioimmunoassay suggests that these studies should be re-evaluated, with greater emphasis placed on the role of morphine-6-glucuronide in the clinical effects of morphine.
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Introduction
In a recent study aninohydroxypropylidene diphosphonate was found to give better long term-control of hypercalcaemia of cancer than either mithramycin or corticosteroids plus calcitonin.' In the short term, however, aminohydroxypropylidene diphosphonate was the least effective agent because of its slow onset of action. We report the effects of combined treatment with aminohydroxypropy- Conversion: SI to tradiinal units-Calcium: 1 mmol/14-0 mg/100 ml. Urine creatine: 1 mmol-0 I g. agents were given for six consecutive days along with continued saline infusions of 2 litres daily to prevent dehydration. Biochemical measurements were made on fasting blood and urine samples using an autoanalyser (Technicon). Serum calcium estimation was adjusted for albumin concentration.' The paired Wilcoxon test was used for statistical analysis.
Results
Both serum calcium and the urinary calcium to creatinine ratio fell signlificantly and progressively between days 1 and 12 (figure). Urinary hydroxyproline to creatinine ratio also fell from a mean (SEM) of 63 (9-1) [umol/mmol before treatment (normal <30 itmol/mmol) to 38 (9-1) inol/mmol on day 1 and 42 (8-3) jmol/mmol on day 12 (p<0-02-and p<005 respectively compared with pretreatment value). Serum creatinine concentration fell from 152 (22 5) jmolIl (1-7 (0-3) mg/100 ml) at presentation (normal 40-130 pmol/l; 0-5-1-5 mg/100 ml) to 129 (20 9) jimol/l (1-5 (0-2) mg/100 ml) after rehydration (p<0 05). Creatinine fell further to 110 (19-6) iLmoll (1-2 (0 2) mg/100 ml) on day 1 and 99 (20 5) imol/l (1-1 (0-2) mg/100 ml) on day 12 (p<0-02 and p<0O05 compared with pretreatment value).
In terms of the "normal" relation between the serum calcium concentration and excreted calcium per unit of glomerular filtrate (CaE) the calcium lowering effect of drug treatment was due to a further fall in renal tubular calcium reabsorption from that achieved by rehydration and to a reduction in filtered calcium load, as reflected by a downward and leftward shift of the serum calcium v CaE points between days 1 and 6 (figure, inset). The fall in filtered calcium load was in turn due mainly to reduced bone resorption (as reflected by the calcium to creatinine ratios) but partly to an improvement in glomerular filtration rate. After treatment was stopped (days 9, 12) the calcium v CaE points shifted vertically downwards, indicating that renal tubular calcium reabsorption had risen though bone resorption remained suppressed.
Discussion
In this study the rapid calcium lowering effect was largely due to an acute reduction in both bone resorption and renal tubular calcium reabsorption. A similar response was reported using the combination of corticosteroids and calcitonin' and was probably mediated by the renal and skeletal effects of calcitonin itself.2 In accordance with previous findings, the reduction in renal tubular calcium reabsorption was sustained for the duration of treatment but not thereafter, and indeed in the longer term control of hypercalcaemia was achieved by suppression of bone resorption. This was almost certainly due to the more prolonged antiosteoclastic effect of the aminohydroxypropylidene diphosphonate.3 The small increase in urinary hydroxyproline to creatinine ratios which remained after treatment probably reflected release of hydroxyproline from non-skeletal tissues.' In all cases correction of hypercalcaemia was associated with an improvement in symptoms in the absence ofany drug related sideeffects.
In this study the combination of aminohydroxypropylidene diphosphonate and calcitonin gave better long term control of hypercalcaemia than the corticosteroid and calcitonin regimen-used previously and was more rapidly acting than aminohydroxypropylidene diphosphonate used alone.' Moreover, we encountered none of the serious side effects which limit the use of other drugs such as mithramycin and intravenous phosphate.4 Combined treatment with aminohydroxypropylidene diphosphonate and calcitonin may therefore be regarded as the treatment of choice in severe hypercalcaea when a rapid but sustained effect is desired. As the main action of calcitonin was to "buy time" during the initial 48 hours while the diphosphonate took effect, it may be possible to limit use of calcitonin to this period with obvious advantages in terms of cost.
